Title: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
Authors: Piccart, M ×
Hortobagyi, G N
Campone, M
Pritchard, K I
Lebrun, F
Ito, Y
Noguchi, S
Perez, A
Rugo, H S
Deleu, I
Burris, H A
Provencher, L
Neven, Patrick
Gnant, M
Shtivelband, M
Wu, C
Fan, J
Feng, W
Taran, T
Baselga, J #
Issue Date: Dec-2014
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:25 issue:12 pages:2357-62
Article number: 10.1093/annonc/mdu456
Abstract: The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is presented here.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science